Applied
DNA Sciences, Inc. (NASDAQ:APDN), announced today that American &
Efird (A&E), a portfolio company of Elevate Textiles and the world’s
foremost manufacturer and distributor of industrial and consumer sewing
thread, embroidery thread and technical textiles, has announced it will
be previewing its new line of advanced identification threads, branded
“Integrity” later this month. A&E will publicly display this latest
breakthrough at the upcoming Texprocess trade show in Frankfurt Germany.
“One of the big challenges brands face today centers around
authenticity. Loss of revenue, reputation, and brand trust are some of
the potential outcomes of counterfeit products,” said A&E President,
Chris Alt. “We are looking forward to previewing our new ‘Integrity’
line at the upcoming Texprocess show in Frankfurt.”
Well known for its leadership role in innovation, product quality, and
sustainability, A&E supports many of the world’s top industrial and
consumer brands with thread products that require strict quality and
performance. A&E’s new “Integrity” thread line provides a tool which
adds advanced identification for greater visibility and transparency
into their product creation process.
“Our collaboration with A&E to adopt the CertainT®
platform globally is a key breakthrough for brands, which have not had
the benefit of forensic systems to help them resolve counterfeit and
diversion in their supply chains. We look forward to providing our full
spectrum molecular brand assurance that also includes forensic expert
witness and authentication services to support A&E and its customers in
apparel, footwear, automotive, military and beyond,” stated Dr. James
Hayward, president and CEO of Applied DNA.
To learn more on A&E’s “Integrity” molecular-tagged thread products,
please visit amefird.com.
Media: Materials and images are available via download.
About American & Efird
A&E, a portfolio company of Elevate Textiles, is the foremost
manufacturer and distributor of premium quality industrial and consumer
sewing thread, embroidery thread and technical textiles. Producers of
apparel, automotive components, home furnishings, medical supplies,
footwear and a diverse range of industrial products rely on A&E
industrial sewing thread to manufacture their products. Customers select
A&E as the preferred choice for industrial sewing thread, embroidery
thread and technical textiles because of A&E’s dedication to providing
its customers with the finest products and services, at the highest
quality, delivered globally. Through its global network, A&E’s products
are manufactured in 22 countries, distributed in 50 countries and sold
in over 100 countries. In addition to A&E’s steadfast commitment to
superior quality and customer service, A&E is a recognized industry
leader in environmental sustainability and corporate social
responsibility and operates its global facilities with the utmost regard
for the safety and health of its associates employed worldwide. A&E owns
or operates 28 manufacturing facilities and employs over 10,000
associates around the world directly or in partnership with joint
venture partners.
For more information, please visit amefird.com.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply
chain security, anti-counterfeiting and anti-theft technology, product
genotyping and pre-clinical nucleic acid-based therapeutic drug
candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect
products, brands, entire supply chains, and intellectual property of
companies, governments and consumers from theft, counterfeiting, fraud
and diversion.
Visit adnas.com
for more information. Follow us on Twitter
and LinkedIn.
Join our mailing
list.
Common stock listed on NASDAQ under the symbol APDN, and warrants are
listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private Securities
Litigation Act of 1995. Forward-looking statements describe Applied
DNA’s future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and uncertainties,
many of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to its history of net
losses, limited financial resources, limited market acceptance , the
uncertainties inherent in research and development, future clinical data
and analysis, including whether any of Applied DNA’s product candidates
will advance further in the preclinical research or clinical trial
process, including receiving clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive final
approval from the U.S. FDA or equivalent foreign regulatory agencies,
and various other factors detailed from time to time in Applied DNA’s
SEC reports and filings, including our Annual Report on Form 10-K filed
on December 18, 2018 and our subsequent quarterly report on Form 10-Q
filed on February 7, 2019, and other reports we file with the SEC, which
are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190508005208/en/